Results 161 to 170 of about 29,382 (269)

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, Volume 13, Issue 25, 4 May 2026.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source

NAD+‒circadian rhythm coupling in dementia

Alzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract The circadian rhythm system and sleep coordinate whole‐body functions across the 24‐h cycle, yet these rhythms progressively deteriorate with neurodegenerative diseases, including dementia. Growing evidence indicates that nicotinamide adenine dinucleotide (NAD+) interacts with the circadian system through multiple molecular pathways and that ...
Shi‐qi Zhang, Jiyeon Lee, Jun‐ping Pan, Rune Enger, Harald Hrubos‐Strøm, Erik S. Musiek, Evandro Fei Fang, Weidong Le   +7 more
wiley   +1 more source

MicroRNA‐Mediated Regulation of Brain Aging Hallmarks: Implications for Neurodegeneration and Neural Recovery

Brain and Behavior, Volume 16, Issue 5, May 2026.
Hallmarks of brain aging regulated by microRNAs (miRNAs). This graphical abstract illustrates the central role of miRNAs in coordinating key biological processes associated with brain aging. miRNAs regulate multiple interconnected hallmarks, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis and impaired ...
Mustafa T. Ardah, Pareshkumar N. Patel, Omayma Salim Waleed, Jamuna K. V., Vandana Tripathi, L. Lakshmi, Rajashree Panigrahi, Manoj Kumar Mishra   +7 more
wiley   +1 more source

Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective?

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Ovarian Cancer (OC), the deadliest gynecological malignancy, poses a major therapeutic challenge in advanced stages owing to its high recurrence rate and metastatic potential. In this regard, it is noteworthy that immunotherapy has recently gained significant attention in OC treatment, a phenomenon attributable to notable advances in over‐the ...
Liying Wang, Yisen Cao, Yuan Ren, Yuhang Zhang, Liang Wang   +4 more
wiley   +1 more source

Cryptocaryone Exhibits ROS/MAPK‐Dependent Antiproliferative and Apoptosis‐Inducing Effects on Triple‐Negative Breast Cancer Cells and Proof‐of‐Concept Breast Cancer Mouse Model

Drug Development Research, Volume 87, Issue 3, May 2026.
ABSTRACT Omics’ technologies have enabled clinicians to gain previously unprecedented insights into the molecular complexity and clinical heterogeneity of triple‐negative breast cancer (TNBC). Increasingly it is being realized that TNBC does not respond well to current targeted therapies.
Ya‐Ting Chuang, Wangta Liu, Tsu‐Ming Chien, Ammad Ahmad Farooqi, Hsun‐Shuo Chang, Jun‐Ping Shiau, Hsueh‐Wei Chang   +6 more
wiley   +1 more source

Homoisoflavonoids—From Natural Specificity and Biosynthesis to Precision Health‐Promoting Mechanisms

Food Frontiers, Volume 7, Issue 3, May 2026.
Homoisoflavonoids are rare flavonoids with a unique bi‐aromatic oxygen‐heterocyclic structure. This review synthesizes their structure–activity relationships in anti‐inflammatory, hypoglycemic, and anticancer contexts. By highlighting their specific natural distribution and outlining biosynthetic pathways, it provides a conceptual framework and ...
Jing Zhang, Han Chen, Jinping Si, Zhigang Han, Xinfeng Zhang   +4 more
wiley   +1 more source

Limitations of Subgroup Safety Analyses for Drug–Drug Interaction Evaluation: Insights from the Talazoparib P‐gp Inhibitor Case

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Impact of concomitant medications (conmeds) on the safety of the investigational agent is often evaluated using subgroup analyses for safety events in patients who received the conmed versus those who did not. Here, we highlight the potential biases and inconclusive results that can arise from such analyses, using talazoparib and P ...
Diane Wang, Charvi Nanavati, Derek Z. Yang, Liza DeAnnuntis, Mohamed Elmeliegy   +4 more
wiley   +1 more source

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation

The Prostate, Volume 86, Issue 6, Page 727-731, May 2026.
ABSTRACT Background Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi).
Mayuko Kanayama, Violet A. Daniels, Marta Gielzak, Alex Brame, Misop Han, Li Jia, Jianfeng Xu, Tamara L. Lotan, Mario A. Eisenberger, Catherine H. Marshall, Patrick C. Walsh, William B. Isaacs, Jun Luo   +12 more
wiley   +1 more source

Cyclic ADP-Ribose and NAADP in Vascular Regulation and Diseases. [PDF]

Messenger (Los Angel), 2013
Li PL, Zhang Y, Abais JM, Ritter JK, Zhang F.   +4 more
europepmc   +1 more source

From “Passive Supplementation” to “Active Repair”: Melatonin Reshapes the Treatment Paradigm for Late‐Onset Hypogonadism by Targeting Leydig Cell Senescence

Aging Cell, Volume 25, Issue 5, May 2026.
Melatonin restores testosterone production in aging Leydig cells by targeting key pathological drivers, particularly oxidative stress and mitochondrial dysfunction. This approach offers a fundamental strategy to reshape the Late‐onset hypogonadism treatment paradigm.
Hui Wu, Gang Ning, Mintao Jian, Ajian Peng, Haoyu Wang, Bonan Li, Xing Zhou   +6 more
wiley   +1 more source